Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Rhabdomyosarcoma | Research

Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival

Authors: Dan Zhao, Fang Zhou, Weixin Liu, Zhou Huang, Xiaolong Xu, Baomin Zheng, Changqing Liu, Chujie Bai, Jiayong Liu, Yan Sun, Weihu Wang, Shaowen Xiao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Adult head and neck rhabdomyosarcoma (HNRMS) is an exceptionally rare malignancy, and there is a paucity of data and research dedicated to understanding its characteristics and management in adult populations. This study aimed to assess the outcomes and identify survival predictors in adult HNRMS.

Methods

We retrospectively evaluated 42 adult patients (> 16 years) with HNRMS who received radiotherapy (RT)-based treatment at our institute between 2008 and 2022. We analysed the clinical characteristics and prognosis of these patients, including the locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS), using the Kaplan–Meier method. The chi-square and Fisher’s exact tests were used to analyse differences between groups for dichotomous and categorical variables, respectively. Survival rates were calculated using the Kaplan–Meier method. Prognostic variables were assessed through univariate Cox analyses.

Results

The median patient age was 28 years (range, 16–82 years). Alveolar RMS was the most common histological type, observed in 21 patients (50.0%), followed by embryonal in 16 patients (38.1%). The anatomic sites of origin were orbital in one (2.4%), parameningeal in 26 (61.9%), and non-orbital/non-parameningeal in 15 (35.7%) patients. Nineteen patients (45.2%) had regional lymph node metastasis, and five patients (11.9%) presented with distant metastatic disease. Distant metastasis (n = 17) was the primary cause of treatment failure. At a median follow-up of 47.0 months, the 5-year LRFS, PFS, and OS rates were 69.0%, 39.7%, and 41.0%, respectively. Univariate analysis revealed that tumour size, lymph node involvement, and the local treatment pattern (surgery and RT vs. RT alone) were significant predictors of survival.

Conclusions

The main failure pattern in patients with HNRMS receiving RT-based treatment was distant metastasis. Tumour size > 5 cm and lymph node involvement were predictors of worse LRFS. Multimodality local treatment, combining surgery and RT, is effective and provides survival benefits.
Literature
1.
go back to reference Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571–80.CrossRefPubMed Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571–80.CrossRefPubMed
2.
go back to reference Hahn E, Barot S, O’Sullivan B, Huang SH, Gupta A, Hosni A, et al. Adult head and neck rhabdomyosarcoma: management, outcomes, and the effect of intensity-modulated radiation therapy on locoregional control. Adv Radiat Oncol. 2022;7:101055.CrossRefPubMedPubMedCentral Hahn E, Barot S, O’Sullivan B, Huang SH, Gupta A, Hosni A, et al. Adult head and neck rhabdomyosarcoma: management, outcomes, and the effect of intensity-modulated radiation therapy on locoregional control. Adv Radiat Oncol. 2022;7:101055.CrossRefPubMedPubMedCentral
3.
go back to reference Newton WA Jr., Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification–an Intergroup Rhabdomyosarcoma tudy. Cancer. 1995;76:1073–85.CrossRefPubMed Newton WA Jr., Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification–an Intergroup Rhabdomyosarcoma tudy. Cancer. 1995;76:1073–85.CrossRefPubMed
4.
go back to reference Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 2006;130:1454–65.CrossRefPubMed Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 2006;130:1454–65.CrossRefPubMed
5.
go back to reference Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology, and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009;27:3391–7.CrossRefPubMed Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology, and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009;27:3391–7.CrossRefPubMed
6.
go back to reference Owosho AABCD, Huang SC, Chen S, Kashikar S, Estilo CL, Wolden SL, et al. A clinicopathological study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcomes. Oral Oncol. 2016;61:89–97.CrossRefPubMedPubMedCentral Owosho AABCD, Huang SC, Chen S, Kashikar S, Estilo CL, Wolden SL, et al. A clinicopathological study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcomes. Oral Oncol. 2016;61:89–97.CrossRefPubMedPubMedCentral
7.
go back to reference Blank LE, Koedooder K, Pieters BR, van der Grient HN, van de Kar M, Buwalda J, et al. The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head and neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys. 2009;74:1555–62.CrossRefPubMed Blank LE, Koedooder K, Pieters BR, van der Grient HN, van de Kar M, Buwalda J, et al. The AMORE protocol for advanced-stage and recurrent nonorbital rhabdomyosarcoma in the head and neck region of children: a radiation oncology view. Int J Radiat Oncol Biol Phys. 2009;74:1555–62.CrossRefPubMed
9.
go back to reference Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup Rhabdomyosarcoma study-IV: results for patients with non-metastatic disease. J Clin Oncol. 2001;19:3091–102.CrossRefPubMed Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup Rhabdomyosarcoma study-IV: results for patients with non-metastatic disease. J Clin Oncol. 2001;19:3091–102.CrossRefPubMed
10.
go back to reference Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Tthird intergroup rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30.CrossRefPubMed Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Tthird intergroup rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30.CrossRefPubMed
11.
go back to reference Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001;234:215–23.CrossRefPubMedPubMedCentral Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001;234:215–23.CrossRefPubMedPubMedCentral
12.
go back to reference Fischer TD, Gaitonde SG, Bandera BC, Raval MV, Vasudevan SA, Gow KW, et al. Pediatric-protocol of multimodal therapy is associated with improved survival in AYAs and adults with rhabdomyosarcoma. Surgery. 2018;163:324–9.CrossRefPubMed Fischer TD, Gaitonde SG, Bandera BC, Raval MV, Vasudevan SA, Gow KW, et al. Pediatric-protocol of multimodal therapy is associated with improved survival in AYAs and adults with rhabdomyosarcoma. Surgery. 2018;163:324–9.CrossRefPubMed
13.
go back to reference Van Gaal JC, Van Der Graaf WT, Rikhof B, Van Hoesel QG, Teerenstra S, Suurmeijer AJ, et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res. 2012;32:4485–97.PubMed Van Gaal JC, Van Der Graaf WT, Rikhof B, Van Hoesel QG, Teerenstra S, Suurmeijer AJ, et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res. 2012;32:4485–97.PubMed
14.
go back to reference Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, et al. Randomized Phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: a European paediatric soft tissue sarcoma study group and innovative therapies for children with cancer trial. J Clin Oncol. 2021;39:2979–90.CrossRefPubMed Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, et al. Randomized Phase II trial of vincristine-irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: a European paediatric soft tissue sarcoma study group and innovative therapies for children with cancer trial. J Clin Oncol. 2021;39:2979–90.CrossRefPubMed
15.
go back to reference Ruiz-Mesa C, Goldberg JM, Coronado Munoz AJ, Dumont SN, Trent JC. Rhabdomyosarcoma in adults: new perspectives on therapy. Curr Treat Options Oncol. 2015;16:27.CrossRefPubMed Ruiz-Mesa C, Goldberg JM, Coronado Munoz AJ, Dumont SN, Trent JC. Rhabdomyosarcoma in adults: new perspectives on therapy. Curr Treat Options Oncol. 2015;16:27.CrossRefPubMed
16.
go back to reference Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP malignant mesenchymal tumor 89. J Clin Oncol. 2005;23:2618–28.CrossRefPubMed Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP malignant mesenchymal tumor 89. J Clin Oncol. 2005;23:2618–28.CrossRefPubMed
17.
go back to reference Frankart AJ, Breneman JC, Pater LE. Radiation therapy in the treatment of head and neck rhabdomyosarcoma. Cancers (Basel). 2021;13. Frankart AJ, Breneman JC, Pater LE. Radiation therapy in the treatment of head and neck rhabdomyosarcoma. Cancers (Basel). 2021;13.
18.
go back to reference Zhao R, Yu X, Feng Y, Wang J, Chen Y, Mao Y, et al. The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma. Asia Pac J Clin Oncol. 2020;16:266–72.CrossRefPubMed Zhao R, Yu X, Feng Y, Wang J, Chen Y, Mao Y, et al. The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma. Asia Pac J Clin Oncol. 2020;16:266–72.CrossRefPubMed
19.
go back to reference Gerber NK, Wexler LH, Singer S, Alektiar KM, Keohan ML, Shi W, et al. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. Int J Radiat Oncol Biol Phys. 2013;86:58–63.CrossRefPubMedPubMedCentral Gerber NK, Wexler LH, Singer S, Alektiar KM, Keohan ML, Shi W, et al. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. Int J Radiat Oncol Biol Phys. 2013;86:58–63.CrossRefPubMedPubMedCentral
20.
go back to reference Liu YT, Wang CW, Hong RL, Kuo SH. Prognostic factors and treatment outcomes of adult patients with rhabdomyosarcoma after multimodality treatment. Anticancer Res. 2019;39:1355–64.CrossRefPubMed Liu YT, Wang CW, Hong RL, Kuo SH. Prognostic factors and treatment outcomes of adult patients with rhabdomyosarcoma after multimodality treatment. Anticancer Res. 2019;39:1355–64.CrossRefPubMed
21.
go back to reference Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, et al. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Med Oncol. 2019;36:59.CrossRefPubMed Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, et al. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Med Oncol. 2019;36:59.CrossRefPubMed
22.
go back to reference Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, et al. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2013;2:553–63.CrossRefPubMedPubMedCentral Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, et al. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2013;2:553–63.CrossRefPubMedPubMedCentral
23.
go back to reference Hawkins WG, Hoos A, Antonescu CR, Urist MJ, Leung DH, Gold JS, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. 2001;91:794–803.CrossRefPubMed Hawkins WG, Hoos A, Antonescu CR, Urist MJ, Leung DH, Gold JS, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. 2001;91:794–803.CrossRefPubMed
24.
go back to reference Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer. 2002;95:377–88.CrossRefPubMed Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer. 2002;95:377–88.CrossRefPubMed
25.
go back to reference Simon JH, Paulino AC, Ritchie JM, Mayr NA, Buatti JM. Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma. 2003;7:1–7.CrossRefPubMedPubMedCentral Simon JH, Paulino AC, Ritchie JM, Mayr NA, Buatti JM. Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma. 2003;7:1–7.CrossRefPubMedPubMedCentral
26.
27.
go back to reference La Quaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer. 1994;73:109–17.CrossRefPubMed La Quaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer. 1994;73:109–17.CrossRefPubMed
28.
go back to reference Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer. 2004;42:64–73.CrossRefPubMed Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer. 2004;42:64–73.CrossRefPubMed
29.
go back to reference Wu Y, Li C, Zhong Y, Guo W, Ren G. Head and neck rhabdomyosarcoma in adults. J Craniofac Surg. 2014;25:922–5.CrossRefPubMed Wu Y, Li C, Zhong Y, Guo W, Ren G. Head and neck rhabdomyosarcoma in adults. J Craniofac Surg. 2014;25:922–5.CrossRefPubMed
30.
go back to reference Neifeld JP, Maurer HM, Godwin D, Berg JW, Salzberg AM. Prognostic variables in pediatric rhabdomyosarcoma before and after multi-modal therapy. J Pediatr Surg. 1979;14:699–703.CrossRefPubMed Neifeld JP, Maurer HM, Godwin D, Berg JW, Salzberg AM. Prognostic variables in pediatric rhabdomyosarcoma before and after multi-modal therapy. J Pediatr Surg. 1979;14:699–703.CrossRefPubMed
31.
go back to reference Gehan EA, Glover FN, Maurer HM, Sutow WW, Hays DM, Lawrence W Jr, et al. Prognostic factors in children with rhabdomyosarcoma. Natl Cancer Inst Monogr. 1981;56:83–92. Gehan EA, Glover FN, Maurer HM, Sutow WW, Hays DM, Lawrence W Jr, et al. Prognostic factors in children with rhabdomyosarcoma. Natl Cancer Inst Monogr. 1981;56:83–92.
32.
go back to reference Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14:595–603.CrossRefPubMed Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14:595–603.CrossRefPubMed
33.
go back to reference Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma committee. J Clin Oncol. 1990;8:443–52.CrossRefPubMed Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B, et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma committee. J Clin Oncol. 1990;8:443–52.CrossRefPubMed
34.
go back to reference Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001;23:215–20.CrossRefPubMed Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001;23:215–20.CrossRefPubMed
35.
go back to reference Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V Treatment protocols. Sarcoma Intergroup Rhabdomyosarcoma Study Group. 2001;5:9–15. Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V Treatment protocols. Sarcoma Intergroup Rhabdomyosarcoma Study Group. 2001;5:9–15.
36.
go back to reference Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The intergroup rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209–20.CrossRefPubMed Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The intergroup rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209–20.CrossRefPubMed
37.
go back to reference Yang J, Gao J, Hu J, Hu W, Qiu X, Huang Q, et al. Particle beam radiation therapy for head and neck rhabdomyosarcoma in adults. Ann Transl Med. 2022;10:1191.CrossRefPubMedPubMedCentral Yang J, Gao J, Hu J, Hu W, Qiu X, Huang Q, et al. Particle beam radiation therapy for head and neck rhabdomyosarcoma in adults. Ann Transl Med. 2022;10:1191.CrossRefPubMedPubMedCentral
38.
go back to reference Elsebaie MAT, Amgad M, Elkashash A, Elgebaly AS, Ashal GGEL, Shash E, et al. Management of low and intermediate risk adult rhabdomyosarcoma: a pooled survival analysis of 553 patients. Sci Rep. 2018;8:9337.ADSCrossRefPubMedPubMedCentral Elsebaie MAT, Amgad M, Elkashash A, Elgebaly AS, Ashal GGEL, Shash E, et al. Management of low and intermediate risk adult rhabdomyosarcoma: a pooled survival analysis of 553 patients. Sci Rep. 2018;8:9337.ADSCrossRefPubMedPubMedCentral
39.
go back to reference Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.CrossRefPubMed Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.CrossRefPubMed
40.
go back to reference Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.CrossRefPubMed Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.CrossRefPubMed
Metadata
Title
Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival
Authors
Dan Zhao
Fang Zhou
Weixin Liu
Zhou Huang
Xiaolong Xu
Baomin Zheng
Changqing Liu
Chujie Bai
Jiayong Liu
Yan Sun
Weihu Wang
Shaowen Xiao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12079-y

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine